MedTrace Logo

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

NCT05992922 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-25

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety, tolerability and efficacy of IC265 compared to vehicle in participants with signs and symptoms dry eye disease.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

IC265 Ophthalmic Solution 1%

1 drop will be instilled in each eye twice a day

DRUG

Placebo Ophthalmic Solution (Vehicle)

1 drop will be instilled in each eye twice a day

Sponsors & Collaborators

  • Iacta Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-17
Primary Completion
2023-12-19
Completion
2023-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05992922 on ClinicalTrials.gov